Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+0.77%
SPX
+0.83%
IXIC
+1.02%
FTSE
0.00%
N225
+0.06%
AXJO
+0.08%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Overview

Loading chart...

Key Stats

Market Cap
22.65M
Dividend Yield
0.00%
P/E Ratio
-2.26
EPS
-0.48
Revenue
29.62M
Avg. Volume
463.06K

About

What does FGEN do?
FibroGen, headquartered in San Francisco, focuses on developing novel therapeutics for cancer and anemia, with key products including Pamrevlumab and Roxadustat. The company went public on November 14, 2014, and employs 486 staff.
Sector
💻 Health Care
IPO
CEO
Employees
Headquarters
California, USA
Website
http://www.fibrogen.com

Recently from Cashu

publisher logo
Cashu

Please provide the content you want me to summarize into a title.

2 days ago
publisher logo
Cashu

FibroGen's Stock Performance: Key Insights and Future Outlook

4 days ago
publisher logo
Cashu

FibroGen Advances Drug Development Amid Market Volatility, Focusing on Anemia Treatments

20 days ago
Stocks
Health Care
fgen
FibroGen
FGEN
+0.36 (+6.86%)
5.61
USD
At close at Jul 04, 20:39 UTC
Summary
News
Signals
Benchmarks
Financials